Current evidence has revealed the response of peripheral circulating CD8+ Teff cells in patients with tumors to anti-PD-(L)1 therapy and their value in predicting the prognosis of patients with cancer (15, 26, 28, 29, 31, 49). This evidence concerns the gene CD8A and cancer.